Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.04.2023 | News item

JAK inhibitors increase risk of MI, thrombosis, cancer and serious infections

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Studies have shown that the Janus kinase (JAK) inhibitors tofacitinib [Xeljanz] and baricitninb [Oluminant] increase the risk of cancer, myocardial infarction (MI), thrombosis and serious infections compared with tumour necrosis factor-alpha inhibitors in patients with rheumatism and an increased risk of cardiovascular disease, advises the Netherlands pharmacovigilance centre Lareb. …
Metadaten
Titel
JAK inhibitors increase risk of MI, thrombosis, cancer and serious infections
Publikationsdatum
01.04.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-36780-z

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Covid-19-vaccine